title: [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
abstract: Voriconazole and posaconazole are two new triazoles with broad-spectrum antifungal activity. The in vitro activity of these agents was compared with that of fluconazole against 113 clinical isolates of Candida spp. exhibiting a wide range of MICs for fluconazole (< or =0.125 to >64 mg/l). They included 22 C. albicans isolates, 22 C. glabrata, 20 C. tropicalis, 15 C. dubliniensis, 13 C. parapsilosis, 13 C. krusei, 4 C. lusitaniae, 3 C. guilliermondii and 1 C. famata. MICs were determined by broth microdilution test performed according to the National Committee for Clinical Laboratory Standards' M27-A document. Voriconazole and posaconazole were quite active against all Candida spp. isolates, with MIC(90) of 0.25 and 0.5 mg/l, respectively. Fluconazole MIC(50) and MIC(90) were 1 and 32 mg/l. Voriconazole and posaconazole showed in vitro activity against fluconazole-susceptible and -resistant Candida isolates. Higher voriconazole and posaconazole MICs were observed in isolates exhibiting higher fluconazole MICs (>/=16 mg/l) than in those of fluconazole-susceptible isolates (MIC(90) for voriconazole and posaconazole in the fluconazole-resistant isolates were 0.5 mg/l versus 0.06 mg/l for voriconazole and 0.25 mg/l for posaconazole in the fluconazole-susceptible strains). C. dubliniensis was the most susceptible species, and voriconazole the most active antifungal agent against all Candida spp. tested.
authors.affiliation: Servicio de Microbiologia, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain. mcrubio@posta.uni.zar.es
authors.forename: M C
authors.initials: MC
authors.lastname: Rubio Calvo
authors.forename: J
authors.initials: J
authors.lastname: Gil
authors.forename: I
authors.initials: I
authors.lastname: Ramírez de Ocáriz
authors.forename: R
authors.initials: R
authors.lastname: Benito
authors.forename: A
authors.initials: A
authors.lastname: Rezusta
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D002177:Candidiasis / Q000382:microbiology; D025141:Drug Resistance, Fungal; D015725:Fluconazole / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D011743:Pyrimidines / Q000494:pharmacology*; D013045:Species Specificity; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; C101425:posaconazole; D015725:Fluconazole; D065819:Voriconazole
vernacular_title: Actividad in vitro de fluconazol, voriconazol y posaconazol frente a Candida spp.